ERBB2 and breast carcinoma: By leveraging these capabilities, SP-IRIS enables a more comprehensive analysis of exosomal-immune complexes than previously possible and forms the basis of this study investigating the interactions between exosomes, therapeutic antibodies, and their potential impact on treatment efficacy in HER2-positive breast cancer patients.